President Trump Expedites the Rescheduling of Cannabis
January 13, 2026 · 8 min
Why listen
The federal push to reschedule cannabis just changed what doctors and researchers can do with it.
Enjoy the episode?
Subscribe to The Psychedelic Report
In this episode
- What moving cannabis from Schedule I to Schedule III actually means
- How this opens doors for clinical use and medical research
- Why this moment may matter for the future of plant medicine
- What comes next in the federal rescheduling process
About this episode
In this episode of The Psychedelic Report, Dr. Dave Rabin MD, PhD offers timely commentary on a major recent development in U.S. drug policy: the federal directive to expedite the rescheduling of cannabis from DEA Schedule I to Schedule III.
While not yet legalized, this critically important move marks an important acknowledgment of the high degree of safety and medical utility of cannabis and, once rescheduled, will reduce barriers to research, clinical use, and patient access. Dr. Dave breaks down what this shift means, what happens next, and why it may signal a broader turning point for plant medicine and psychedelic research.The White House Announcement concerning Cannabis on Dec 18, 2025
Web: https://thepsychdedelic.reportInstagram: https://www.instagram.com/drdavidrabinTwitter: https://twitter.com/DrDavidRabin
More from Dr. Dave: https://www.drdave.io/
Evidence-Based Guidelines for Treatment of Chronic Pain and Opioid Use Disorders Using Cannabinoids
Learn more about your ad choices. Visit megaphone.fm/adchoices
About The Psychedelic Report
Dr. Dave Rabin MD, PhD, a psychiatrist and neuroscientist trained in Ketamine and MDMA-assisted therapy, brings you the newest developments from the world of psychedelic science and technology. From researchers and investors to physicians and shamans to nonprofit pioneers and policy-makers — each week, Dr.
See all episodes →
